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Abstract This study aimed to examine effects of varied organic
phosphates on activities of soluble guanylate cyclase (sGC). The
enzyme was purified from bovine lung. Physiologically relevant
concentrations of ATP, 2,3-bisphosphoglyceric acid and inositol
hexakisphosphate inhibited its enzyme activities under steady-
state conditions as well as those determined under stimulation
with S-nitroso-N-acetylpenicillamine, a nitric oxide donor,
carbon monoxide or YC-1. Lineweaver^Burk plot analyses
revealed that these three organic phosphates act as competitive
inhibitors. Other organic phosphates such as cardiolipin and
sphingomyelin but not inorganic phosphates exhibited such
inhibitory actions. These results suggest that organic phosphates
serve as inhibitors for sGC-dependent signaling events. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
Key words: Soluble guanylate cyclase; Nitric oxide;
Carbon monoxide; Adenosine triphosphate;
Organic phosphate; 2,3-Bisphosphoglyceric acid
1. Introduction
Guanylate cyclase (GTP pyrophosphate lyase (cyclizing),
EC 4.6.1.2) constitutes a family of enzymes that catalyze the
cyclization of GTP to cGMP [1,2]. There are two general
classes of the cyclase, particulate (pGC) and soluble guanylate
cyclases (sGC). pGC is membrane-bound and activated by
several peptide ligands such as atrial natriuretic peptide [3^
6], while sGC is an important receptor for nitric oxide (NO)
which activates the enzyme to execute signal transduction in
neurovascular systems [7,8]. Other known activators are car-
bon monoxide (CO), another gaseous mediator that binds to
the prosthetic heme of the enzyme [9^11], and YC-1, a syn-
thetic anti-platelet reagent which activates the enzyme through
heme-independent mechanisms [12^14]. On the other hand,
several synthetic inhibitors of the enzyme, such as 1H-
(1,2,4)-oxadiazolo-(4,3-a)-quinoxalin-1-one, have been pro-
vided [15]. However, little information has been available as
to whether endogenous substances occurring in cells could
modulate the sGC activities, except for a previous study show-
ing that adenosine phosphates such as ATP inhibit the cGMP
formation by the enzyme [16]. Considering that cellular con-
tents of organic phosphates have been shown to be altered
dramatically in response to redox changes, it is not unreason-
able to hypothesize that the biologically active organic phos-
phates could regulate the sGC activities and alter the sensi-
tivity of the enzyme to NO. We here examine actions of
various organic phosphates on the sGC activities and provide
evidence that some of them have the ability to inhibit the
activities at their physiologically relevant concentrations.
2. Materials and methods
2.1. Puri¢cation of sGC from bovine lung
sGC was puri¢ed from bovine lung as described previously [17].
sGC-containing fractions were collected by judging the ability to gen-
erate cGMP in response to the NO application. The concentrated
NO-sensitive fractions were further puri¢ed with a Superdex 200 pg
HPLC column (Amersham Pharmacia Biotech, Little Chalfont, Buck-
inghamshire, UK). The fractions with a speci¢c activity over 8000
nmol/min/mg protein measured in the presence of NO were pooled.
Then, the sample was ¢nally puri¢ed to apparent homogeneity with a
Protein Pak G-DEAE HPLC column (Waters, Milford, MA, USA).
Protein contents of the resultant homogeneous enzyme were deter-
mined by the method of Bradford [18]. In order to determine the
purity of the enzyme preparations, the puri¢ed sGC sample was sub-
jected to SDS^PAGE as described elsewhere [19]. The sample was
stored at 380‡C until use.
2.2. Determination of enzyme activity
Reaction mixtures contained 5 mM MgCl2, 3 mM dithiothreitol,
1 mM 3-isobutyl-1-methylxanthine, 1 mM GTP, and 2.5 nM sGC in
40 mM TEA^HCl bu¡er at pH 7.4. Enzyme reactions were conducted
at 37‡C for 10 min and terminated by addition of 30% acetic acid in a
¢nal volume of 1 ml. The guanylate cyclase activity was determined
by measuring the cGMP contents using enzyme-linked immunosorb-
ent assay (Amersham Pharmacia Biotech). S-Nitroso-N-acetylpenicill-
amine (SNAP, Inter Medical, Tokyo, Japan), an NO donor, was dis-
solved in phosphate-bu¡ered saline at pH 7.4, at 30 min prior to the
start of experiments. Desired concentrations of CO were applied to
the enzyme as described previously [11]. YC-1 (Alexis Biochemicals,
San Diego, CA, USA) was dissolved in N,N-dimethylformamide
(DMF). The ¢nal DMF concentration in all samples was 1% (v/v).
All measurements were performed in duplicate and were repeated
three times. Data in the present study are expressed as mean þ S.D.
of measurements. Di¡erences in statistical signi¢cance among groups
were analyzed by one-way ANOVA with Fisher’s multiple compari-
son test, unless indicated otherwise. P6 0.05 was considered statisti-
cally signi¢cant.
2.3. Reagents studied
GTP, adenosine, AMP, ADP, ATP, 2,3-bisphosphoglyceric acid
(2,3-BPG), inositol hexakisphosphate (IHP), phosphoribosyl pyro-
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phosphate (PRPP), phosphatidic acid, phosphatidylethanolamine,
phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phos-
phatidylinositol bisphosphate, sphingosine, sphingosine 1-phosphate,
sphingomyelin, ceramide, and cardiolipin were from Sigma Chemical
Co. (St. Louis, MO, USA). GTP, adenosine, AMP, ADP, ATP, 2,3-
BPG, IHP and PRPP were dissolved in bu¡er to give desired concen-
trations. Other organic phosphates were dissolved with 1% ethanol
and then added to the reaction mixture. In these experiments, the
same concentration of ethanol was added as a vehicle in the control
experiments.
Fig. 1. A representative picture of SDS^PAGE for puri¢ed samples
of sGC. Lane 1 denotes molecular markers. Lane 2 indicates a pat-
tern of puri¢ed sGC (0.2 Wg), displaying two bands with distinct
molecular weights.
Fig. 2. E¡ects of organic and inorganic phosphates on activities of
sGC. The sGC activity was measured under conditions in the ab-
sence of NO, being 77.5 þ 5.5 nmol/min/mg protein, and designated
the control activity. Concentrations of compounds studied were
1 mM in all experiments. Data are means+S.D. of measurements
from three separate experiments. *P6 0.05 as compared with the
control values. Note that tetrapotassium pyrophosphate (PPi) but
not dipotassium hydrogen phosphate (Pi) signi¢cantly attenuates the
control activity.
Fig. 3. Competitive inhibition of the sGC activities by (A) ATP,
(B) 2,3-BPG and (C) IHP revealed by Lineweaver^Burk plot analyses.
Data plots denote means þ S.D. from three independent experiments.
Note that ATP exhibits competitive inhibition with its lower con-
centrations less than 1 mM, while it shows mixed competition pat-
terns at 2 mM.
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3. Results
3.1. Inhibitory actions of ATP, 2,3-BPG and IHP on the
basal activities of sGC
Fig. 1 illustrates a representative picture of SDS^PAGE of
puri¢ed sGC samples. As seen, two subunits of sGC were
noted as judged by distinct molecular weights of 74 and 71
kDa for K and L subunits, respectively. These results indicated
a quality of the enzyme puri¢cation, being in good agreement
with a previous report [17]. Considering that the molecular
weight of bovine sGC is 145 kDa, 1 mg of the sample con-
tained approximately 6.9 nmol of sGC. Using the puri¢ed
sGC sample, e¡ects of ATP and its related compounds on
the enzyme activities were examined. The activities were de-
termined in the absence of e¡ectors such as NO, being des-
ignated the baseline activity. E¡ects of these reagents were
examined at a ¢nal concentration of 1 mM. As seen in Fig.
2, ATP signi¢cantly attenuated the baseline activity. ADP and
AMP also inhibited the activities but with smaller extents of
the inhibition than ATP, indicating that their inhibitory ac-
tions were reduced in parallel with the decreasing number of
phosphates. On the other hand, adenosine did not alter the
baseline activity. These results were in agreement with a pre-
vious observation in experiments using crude sGC preparation
from rat lung [16]. Other types of organic phosphates such as
2,3-BPG and IHP exhibited potent inhibitory actions on the
enzyme activities. On the other hand, neither PRPP nor dipo-
tassium hydrogen phosphate (Pi) showed such inhibitory ac-
tion, though tetrapotassium pyrophosphate (PPi) displayed a
mild but signi¢cant inhibition on the activities. We next at-
tempted to examine mechanisms for inhibitory actions of
ATP, 2,3-BPG and IHP on the basal enzyme activities. As
seen in Lineweaver^Burk plot analyses in Fig. 3, at concen-
trations less than 1 mM, ATP displayed a competitive inhibi-
tion pattern, showing the intersection on the y-axis. With
higher concentrations, however, the mechanisms appeared to
involve a mixed inhibition pattern, as judged by the intersec-
tion in the left side of the y-axis. On the other hand, both 2,3-
BPG and IHP exhibited a competitive inhibition pattern over
their concentrations examined, and the Ki values were 108 WM
and 9.7 WM, respectively. Considering physiological concen-
trations of these reagents in cells such as human or avian
Fig. 4. E¡ects of ATP, 2,3-BPG and IHP on the allosteric e¡ector-dependent activation of sGC. A: Dose-dependent activation of the sGC ac-
tivities by CO and YC-1. B: Comparison of dose-dependent sGC activation between CO and NO. SNAP was used as a donor of NO. Curves
with arrows in A and B indicate identical data showing CO-dependent activation. Data are means þ S.D. of measurements from three separate
experiments. C: E¡ects of 1 mM ATP, 2 mM 2,3-BPG and 0.3 mM IHP on activities of sGC treated with CO, SNAP and YC-1. Note that
these concentrations of the reagents comparably inhibit the CO-elicited activation of the enzyme. Data indicate mean+S.D. of measurements
from three independent experiments. *P6 0.05 as compared with the control values, 2P6 0.05 as compared with the data showing e¡ects of
ATP.
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erythrocytes and muscle cells [20^22], these results suggest
that physiologically relevant concentrations of ATP, 2,3-
BPG and IHP could suppress the basal sGC activities.
3.2. ATP, 2.3-BPG and IHP attenuate the sGC activation by
CO, NO and YC-1
The observation showing inhibitory actions of ATP, 2,3-
BPG and IHP on the basal sGC activities led us to examine
whether these reagents could also attenuate the enzyme acti-
vation by e¡ectors such as CO, NO and YC-1. As seen in Fig.
4A, CO and YC-1 dose-dependently activated the sGC activ-
ities. At 30 WM, CO increased the sGC activity approximately
by two-fold. As reported previously [13,23], however, the po-
tency of CO to activate sGC was far smaller than that of NO.
As shown by the arrow in Fig. 4B, the dose^response curve
for CO appeared almost £at as compared with that for SNAP.
Actually, the ability of the NO donor SNAP to activate the
enzyme was approximately 50-fold greater than that elicited
by su⁄cient concentrations of CO. We then chose concentra-
tions of ATP, 2,3-BPG and IHP at 1 mM, 2 mM and 0.3 mM,
respectively, which inhibited the CO-elicited activation of the
enzyme approximately by 50% (Fig. 4C). Under these exper-
imental conditions, these organic phosphates signi¢cantly at-
tenuated the SNAP- or YC-1-induced activation of sGC, but
with di¡erent extents of inhibition: among these compounds,
IHP displayed the most potent inhibitory action on the en-
zyme. These results suggest that ATP, 2,3-BPG and IHP in-
hibit the sGC activities irrespective of the presence or absence
of these e¡ectors.
3.3. Biologically active phospholipids inhibit the baseline sGC
activities
The current observation raised a possibility that other or-
ganic compounds with phosphate might alter the sGC activ-
ities. Fig. 5 illustrates e¡ects of varied phospholipids on the
basal enzyme activities. At 1 WM, phosphatidylserine, phos-
phatidylinositol, phosphatidylinositol bisphosphate and cardi-
olipin exhibited a signi¢cant inhibition on the activities.
Among these compounds, cardiolipin had the most potent
inhibitory action on the enzyme, displaying approximately a
75% inhibition. Other phospholipids such as sphingosine 1-
phosphate also displayed a signi¢cant suppression. However,
considering that sphingosine at the same concentration exhib-
ited a comparable inhibition rate, its e¡ect was unlikely to be
ascribable to the action of the phosphate.
4. Discussion
The present study provides evidence that a variety of bio-
logically active organic phosphates have the ability to sup-
press the catalytic activities of sGC in vitro. Among these
sGC-inhibiting substances, 2,3-BPG and IHP appear to block
the activity in a competitive manner, while ATP suppresses
the activity in competitive and non-competitive manners at
low and high concentrations, respectively. The inhibitory ef-
fect of this adenosine derivative was reported in previous ex-
periments using a crude preparation of rat lung sGC [16] or
human placental enzyme [24], but mechanisms for the inhibi-
tion were not fully addressed. The inhibitory e¡ect of the
reagent on sGC activity is reduced with a decreasing number
of phosphates, indicating that ATP is a relatively potent in-
hibitor as compared with other derivatives such as AMP and
adenosine. Furthermore, the present study ¢rst provides evi-
dence that ATP at physiologically relevant concentrations is
able to inhibit NO- or CO-dependent sGC activation in vitro.
Although whether the current results could be extrapolated
to the in vivo system is quite unknown, the direct inhibitory
action of ATP on sGC demonstrated in this study sheds light
on a novel mechanism for regulation of blood £ow under
hypoxic conditions. Several lines of functional linkage of
ATP to compensation of local blood £ow in vivo have been
demonstrated. First, upon ischemia, ATP is rapidly hydro-
lyzed to generate adenosine which accesses to vascular smooth
muscle cells for vasorelaxation [25]. Second, recent studies
suggest that hypoxia triggers the release of ATP from eryth-
rocytes which in turn stimulates purinergic receptor on endo-
thelial cells and evokes NO generation for vasorelaxation [26].
Since the local oxygen concentration is a determinant for the
half-life of NO in situ [27], hypoxia could help NO-mediated
vasodilation to guarantee ample blood supply to the hypoxic
area at risk. Finally, considering the inhibitory action of ATP
on sGC, stimulation of local NO generation could not only
activate sGC directly but also help sGC activation indirectly
through suppression of mitochondrial membrane potential, a
determinant of ATP synthesis in cells [28]. In this context, the
roles of ATP in the regulation of sGC sensitivity to NO de-
serve further study on in vivo evidence for ATP-mediated
regulation of blood supply to hypoxic regions and its func-
tional link to local sGC activities.
It should be noted that in this study cardiolipin possessed a
potent inhibitory action on sGC activity. A recent investiga-
tion revealed the involvement of this phospholipid in the reg-
Fig. 5. E¡ects of di¡erent phospholipids on activities of sGC. PA:
phosphatidic acid; PE: phosphatidylethanolamine; PC: phosphati-
dylcholine; PS: phosphatidylserine; PI: phosphatidylinositol; PIP2 :
phosphatidylinositol bisphosphate; CL: cardiolipin; SP: sphingosine
1-phosphate; S: sphingosine; SM: sphingomyelin; CE: ceramide.
These phospholipid concentrations were 1 WM, dissolved in ethanol
as a vehicle at a ¢nal concentration of 1% (v/v). Data were
means+S.D. of measurements from three independent experiments.
*P6 0.05 as compared with the values in the vehicle group.
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ulation of vasospasm [29]. Under normal conditions, cardio-
lipin binds tightly to the mitochondrial inner membrane. Its
oxidative modi¢cation could cause the reduction of mitochon-
drial membrane potential and the release of cytochrome c into
the cytoplasm to trigger apoptosis [30]. On the other hand, it
is well known that patients with anti-phospholipid antibodies
frequently demonstrate cardiovascular insu⁄ciency or pre-
eclampsia. Recent experimental data have provided evidence
that the injection of cardiolipin into the circulation aggravates
cerebrovascular spasm after subarachnoid hemorrhage in par-
allel with an increase in the titer of anti-cardiolipin antibody
[29]. Although the anti-cardiolipin antibody rather than the
antigen by itself appeared to contribute to the aggravation of
the vascular dysfunction in the previous study, the present
result showing the inhibitory action of cardiolipin on sGC
raises the possibility that the release of this phospholipid
into the circulation could inhibit sGC in and around vascular
walls and/or platelets and thus increase the risk of vasospasm.
The mechanisms for the inhibitory e¡ects of phospholipids on
sGC activities deserve further study on the pathophysiological
implications of this observation at the cell and organ levels.
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